Pier Paolo Olimpieri Selected Research

COVID-19

8/2023	Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study.
1/2022	Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy.
1/2022	Impact of the COVID-19 pandemic on prescription of sacubitril/valsartan in Italy.
1/2022	Under-prescription of direct oral anticoagulants for treatment of non-valvular atrial fibrillation and venous thromboembolism in the COVID-19 lockdown period.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pier Paolo Olimpieri Research Topics

Disease

4	COVID-19 08/2023 - 01/2022
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2023 - 01/2020
2	Immunoglobulin Light-chain Amyloidosis 01/2022 - 01/2022
1	Atherosclerosis 11/2023
1	Homozygous Familial Hypercholesterolemia 11/2023
1	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 11/2023
1	Disease Progression 08/2023
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2023
1	Fibrosis (Cirrhosis) 01/2023
1	Venous Thromboembolism 01/2022
1	Atrial Fibrillation 01/2022
1	Blast Crisis (Blast Phase) 01/2022
1	Heart Failure 01/2022

Drug/Important Bio-Agent (IBA)

2	ponatinibIBA 01/2023 - 01/2022
2	Tyrosine Kinase InhibitorsIBA 02/2021 - 01/2020
1	LDL CholesterolIBA 11/2023
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 11/2023
1	SubtilisinIBA 11/2023
1	Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)IBA 11/2023
1	PCSK9 InhibitorsIBA 11/2023
1	oxidized low density lipoproteinIBA 11/2023
1	alirocumabIBA 11/2023
1	evolocumabIBA 11/2023
1	LipidsIBA 11/2023
1	nirmatrelvirIBA 08/2023
1	Ritonavir (Norvir)FDA Link 08/2023
1	molnupiravirIBA 08/2023
1	Antiviral Agents (Antivirals)IBA 01/2023
1	ibrutinibIBA 01/2023
1	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2022
1	Bortezomib (Velcade)FDA Link 01/2022
1	AnticoagulantsIBA 01/2022
1	Immunoglobulins (Immunoglobulin)IBA 01/2022
1	Immunoglobulin Light Chains (Immunoglobulin Light Chain)IBA 01/2022
1	remdesivirIBA 01/2022

Therapy/Procedure

2	Therapeutics 11/2023 - 01/2022